Company / Shareholders' Equity
ROCKET PHARMACEUTICALS, INC. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$463.2M
FY2025
5-year range
$307.3M / $503.5M
FY2021-FY2025
Trend
-6.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 8 years, ranging from $16M in FY2019 to $504M in FY2022.
Based on SEC 10-K filings.
$463M in FY2025 with a 5-year CAGR of +19.0%.
Remained stable around $463M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -2.7%
- 5-Year CAGR
- +19.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +19.0%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 6.0% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
- Lowest shareholders' equity in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $463.2M | -6.0% |
| FY2024 | $492.6M | +8.3% |
| FY2023 | $454.7M | -9.7% |
| FY2022 | $503.5M | +63.9% |
| FY2021 | $307.3M | +58.4% |
| FY2020 | $194.0M | +1150.3% |
| FY2019 | $15.5M | +0.0% |
| FY2018 | $15.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026